|
|
Article: Collegium Pharmaceutical Provides Update on Development of its Nasal Inhaled Steroid for Allergic Rhinitis.
- Article from:
- Business Wire
- Article date:
- August 15, 2007
CopyrightCOPYRIGHT 2007 Business Wire. This material is published under license from the publisher through the Gale Group, Farmington Hills, Michigan. All inquiries regarding rights should be directed to the Gale Group. (Hide copyright information)
|
Expects to file for FDA Approval by the end of 2007
CUMBERLAND, R.I. -- Collegium Pharmaceutical, Inc., a specialty pharmaceutical company with a focus on respiratory and CNS disorders, today announced an update on the development of its most advanced prescription product candidate for the treatment of allergic rhinitis. Collegium previously announced that it had acquired, from Muro Pharmaceutical, Inc., all rights to its Tri-Nasal[R] (triamcinolone acetonide, USP) Nasal Spray, including the product's approved NDA and the right to market the product. Triamcinolone acetonide is the same active ingredient found in Nasacort[R] AQ (Aventis) which had 2006 US sales of ...